It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Adapting one’s attitudes and behaviors to group norms is essential for successful social interaction and, thus, participation in society. Yet, despite its importance for societal and individual functioning, the underlying neuropharmacology is poorly understood. We therefore investigated its neurochemical and neural correlates in a pharmacological functional magnetic resonance imaging study. Lysergic acid diethylamide (LSD) has been shown to alter social processing and therefore provides the unique opportunity to investigate the role of the 5-HT2A receptor in social influence processing. Twenty-four healthy human volunteers received either (1) placebo + placebo, (2) placebo + LSD (100 µg), or (3) the 5-HT2A receptor antagonist ketanserin (40 mg) + LSD (100 µg) at three different occasions in a double-blind, randomized, counterbalanced, cross-over design. LSD increases social adaptation but only if the opinions of others are similar to the individual’s own. These increases were associated with increased activity in the medial prefrontal cortex while participants received social feedback. Furthermore, pretreatment with the 5-HT2A antagonist ketanserin fully blocked LSD-induced changes during feedback processing, indicating a key role of the 5-HT2A system in social feedback processing. Our results highlight the crucial role of the 5-HT-system in social influence and, thus, provide important insight into the neuropharmacological basis of social cognition and behavior.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University Hospital for Psychiatry Zurich, Neuropsychopharmacology and Brain Imaging, Department of Psychiatry, Psychotherapy and Psychosomatics, Zürich, Switzerland (GRID:grid.412004.3) (ISNI:0000 0004 0478 9977)
2 Max Planck Institute of Psychiatry, Independent Max Planck Research Group for Social Neuroscience, Munich, Germany (GRID:grid.419548.5) (ISNI:0000 0000 9497 5095); Ludwig-Maximilians-Universität, Department of Psychiatry, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X); LVR Klinikum Düsseldorf/Kliniken der Heinrich-Heine-Universität Düsseldorf, Clinic for Disorders of Social Interaction, Düsseldorf, Germany (GRID:grid.411327.2) (ISNI:0000 0001 2176 9917)
3 University Hospital for Psychiatry Zurich, Department of Psychiatry, Psychotherapy and Psychosomatics, Zurich, Switzerland (GRID:grid.412004.3) (ISNI:0000 0004 0478 9977)